Amarin Sinks to Five-Month Low After Losing Ruling on Heart Drug

(Bloomberg) -- Amarin Corp. fell to the lowest since March after it lost its bid to revive patents on the heart medicine Vascepa, its only product, a decision that opens the door to generic competi...
BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.